Table 1.
Complex N=1201 | Atypia N=242 | |||
---|---|---|---|---|
No Progestin N=164 |
Progestin > 14d N=1037 |
No Progestin N=62 |
Progestin > 14d N=180 |
|
Age (years) | ||||
<39 | 17(10.4) | 79(7.6) | 4(6.5) | 13(7.2) |
40-49 | 50(30.5) | 314(30.3) | 16(25.8) | 35(19.4) |
50-59 | 59(36.0) | 415(40.0) | 16(25.8) | 64(35.6) |
60-69 | 23(14.0) | 145(14.0) | 15(24.2) | 43(23.9) |
≥70 | 15(9.1) | 84(8.1) | 11(17.7) | 25(13.9) |
Caucasian1 | 128(82.1) | 907(89.3) | 55(90.2) | 156(90.2) |
Diabetes1 | 13(8.3) | 82(8.1) | 6(9.8) | 21(12.1) |
Breast/Colon Cancer1 |
15(9.1) | 23(2.2) | 3(4.8) | 13(7.2) |
Current Smoker1 | 12(8.3) | 117(12.1) | 9(15.5) | 21(12.6) |
BMI (kg/m2)1 | ||||
<25 | 42(27.5) | 329(33.1) | 19(31.2) | 56(32.2) |
25 – 29.9 | 32(20.9) | 260(26.2) | 14(23.0) | 39(22.4) |
≥30 | 79(51.6) | 404(40.7) | 28(45.8) | 79(45.4) |
Nulliparous1 | 32(20.5) | 158(15.6) | 13(21.3) | 32(18.5) |
Oral contraceptive2 | 4(2.4) | 13(1.3) | 1(1.6) | 1(0.6) |
Estrogen + Progestin2,3 |
0(0) | 165(15.9) | 4(6.5) | 24(13.3) |
Unopposed Estrogen2,4 |
6(3.7) | 143(13.8) | 7(11.3) | 28(15.6) |
Progestin only2 | 0(0) | 11(1.1) | 0(0) | 4(2.2) |
Index biopsy year | ||||
1985 – 1989 | 32(19.5) | 233(22.5) | 19(30.7) | 56(31.1) |
1990 – 1994 | 37(22.6) | 364(35.1) | 14(22.6) | 52(28.9) |
1995 – 1999 | 46(28.0) | 291(28.0) | 19(30.7) | 42(23.3) |
2000 – 2005 | 49(29.9) | 149(14.4) | 10(16.1) | 30(16.7) |
Missing data. d = days. BMI = body mass index.
Dispensed for at least 2 months in the 6 months preceding diagnosis of endometrial hyperplasia.
Estrogen + progestin = postmenopausal hormone therapy (the progestin was dispensed for at least 1/3 of the time that the estrogen was dispensed).
Unopposed Estrogen = postmenopausal hormone therapy (estrogen alone or estrogen plus progestin where progestin was dispensed less than 1/3 of the time that estrogen was dispensed).